✦ LIBER ✦

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations

✍ Scribed by Hiramatsu, Miyako; Ninomiya, Hironori; Inamura, Kentaro; Nomura, Kimie; Takeuchi, Kengo; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Yamori, Takao; Matsuura, Masaaki; Morikawa, Toshiaki; Ishikawa, Yuichi

Book ID: 119320329
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 492 KB
Volume: 70
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2010.01.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of EGFR and KRAS mutations in

Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect

✍ Munfus-McCray, Delicia; Cui, Min; Zhang, Zhen; Gabrielson, Edward; Askin, Freder 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 177 KB

Biological Characteristics and Epidermal

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

✍ Lu, Rong-li; Hu, Cheng-Ping; Yang, Hua-ping; Li, Yuan-yuan; Gu, Qi-hua; Wu, Liel 📂 Article 📅 2013 🏛 Springer Netherlands 🌐 English ⚖ 221 KB

Activating Mutations in the Tyrosine Kin

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

✍ Taron, M. 📂 Article 📅 2005 🏛 American Association for Cancer Research 🌐 English ⚖ 457 KB

9166 Activity of BIBW 2992, an irreversi

9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

✍ De Greve, J.; Teugels, E.; Geers, C.; DeMey, J.; in 'tveld, P.; Decoster, L.; Ta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB

PD-159 Mutation in the tyrosine kinase d

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB